Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss

American Journal of Physiology - Endocrinology and Metabolism

Volumn 294, Issue 6, 2008, Pages

  Knapp, Philip E ^a,d   Storer, Thomas W ^a   Herbst, Karen L ^c   Singh, Atam B ^c   Dzekov, Connie ^c   Dzekov, Jeanne ^c   LaValley, Michael ^b   Zhang, Anqi ^a   Ulloor, Jagadish ^a   Bhasin, Shalender ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

Androgens; Body composition; Quality of life; Randomized controlled trial; Sexual function

Indexed keywords

BILIRUBIN; HEMOGLOBIN; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING PROTEIN; TESTOSTERONE; TESTOSTERONE ENANTATE; DRUG DERIVATIVE;

ACNE; ADULT; AGGRESSION; ANXIETY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FATIGUE; FITNESS; GYNECOMASTIA; HAIR GROWTH; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEAN BODY WEIGHT; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MOOD; MUSCLE FUNCTION; MUSCLE STRENGTH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRESS; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION; ADOLESCENT; AFFECT; BLOOD; BODY COMPOSITION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; WALKING;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AFFECT; BODY COMPOSITION; DOUBLE-BLIND METHOD; FATIGUE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; QUALITY OF LIFE; QUESTIONNAIRES; STATISTICS, NONPARAMETRIC; TESTOSTERONE; WALKING; WEIGHT LOSS;

EID: 47549114457     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90213.2008     Document Type: Article

References (50)

1. Baechle T, Earle R, Wathen D. Resistance training. In: Essentials of Strength Training and Conditioning, edited by Baechle T, Earle R. Champaign, IL: Human Kinetics, 2000, p. 407-409.
2. Bassey EJ, Fentem PH, MacDonald IC, Scriven PM. Self-paced walking as a method for exercise testing in elderly and young men. Clin Sci Mol Med Suppl 56: 609-612, 1976.
3. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 10: 1657-1662, 1996.
4. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 3: 146-159, 2006.
5. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91: 1995-2010, 2006.
6. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, Shikuma CM, for the AIDS Clinical Trials Group Protocol A5079 Study Team. Effects of testosterone supplementation on whole body and regional fat mass distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 92: 1049-1057, 2007.
7. Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, Beall G. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83: 3155-3162, 1998.
8. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supra-physiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1-7, 1996.
9. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283: 763-770, 2000.
10. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281: E1172-E1181, 2001.
11. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as younger men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90: 678-688, 2005.
12. Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 84: 1288-1293, 1989.
13. Choi HH, Gray PB, Storer TW, Calof OM, Woodhouse L, Singh AB, Padero C, Mac RP, Sinha-Hikim I, Shen R, Dzekov J, Dzekof C, Kushnir MM, Rockwood AL, Meikle AW, Lee ML, Hays RD, Bhasin S. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab 90: 1531-1541, 2005.
14. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS 11: 1347-1352, 1997.
15. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr 7: 46-51, 1994.
16. Cuerda C, Zugasti A, Breton I, Camblor M, Miralles P, Garcia P. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men. Nutr Clin Pract 20: 93-97, 2005.
17. Dobs AS, Cofrancesco J, Nolten WE, Danoff A, Anderson R, Hamilton CD, Feinberg J, Seekins D, Yangco B, Rhame F. The use of a transscrotal delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107: 126-132, 1999.
18. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N, Klibanski A. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129: 18-26, 1998.
19. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, Stanley T, Shoenfeld D, Burrows B, Hayden D, Basgoz N, Klibanski A. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. Ann Intern Med 133: 348-355, 2000.
20. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism on depression indices in HIV-infected men. J Clin Endocrinol Metab 85: 60-65, 2000.
21. Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 41: 304-314, 2006.
22. Guenter P, Muurahainen N, Simons G, Kosok A, Cohan GR, Rudenstein R, Turner JL. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 6: 1130-1138, 1993.
23. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82: 29-39, 2007.
24. Hellerstein MK, Kahn J, Mudie H, Viteri F. Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 17: 17-33, 1990.
25. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol 59A: 75-78, 2004.
26. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2: 692-699, 2002.
27. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50: 444-447, 1989.
28. Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 116: 320-328, 1992.
29. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the depression stress anxiety scales (DASS) with the Beck depression and anxiety inventories. Behav Res Ther 33: 335-342, 1995.
30. Margaria R, Aghemo P, Rovelli E. Measurement of muscular power (anaerobic) in man. J Appl Physiol 21: 1662-1664, 1966.
31. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 15: 43-48, 1997.
32. Mulligan K, Zackin R, Clark RA, Alston-Smith B, Liu T, Sattler FR, Delvers TB, Currier JS. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss. Arch Intern Med 165: 578-585, 2005.
33. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Man CD, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647-1659, 2006.
34. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover L. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90: 1502-1510, 2005.
35. Perry PJ, Yates WR, Williams RD, Andersen AE, MacIndoe JH, Lund BC, Holman TL. Testosterone therapy in late-life major depression in males. J Clin Psychiatry 63: 1096-1101, 2002.
36. Pope HG, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 160: 105-111, 2003.
37. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 24: 379-385, 2004.
38. Rabkin JG, Wagner GJ, Rabkin R. A double-blind placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 57: 141-147, 2000.
39. Shamlian NT, Cole MG. Androgen treatment of depressive symptoms in older men: a systematic review of feasibility and effectiveness. Can J Psychiatry 51: 295-299, 2006.
40. Sherer R. Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting. Semin Oncol 25: 92-97, 1998.
41. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88: 1478-1485, 2003.
42. Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder T, Beck K, Padero M, Mac P, Yarasheski KE, Geurts P, Willemsen A, Harms MK, Bhasin S. A randomized, placebo controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss and recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90: 4474-4482, 2005.
43. Strawford A, Barbieri T, Van Loan M, Parks E, Catlin D, Barton N, Neese R, Christiansen M, King J, Hellerstein MK. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA 281: 1282-1290, 1999.
44. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666-3672, 1999.
45. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 81: 3578-3583, 1996.
46. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85: 2839-2853, 2000.
47. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31: 803-805, 2000.
48. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, Bartsch GE. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18: 80-85, 1998.
49. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr 24: 137-146, 2000.
50. Wu AW, Rubin HR, Mathews WC, Ware JE, Brysk LT, Hardy WD, Bozzette SA, Spector SA, Richman DD. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 29: 786-798, 1991.